BRPI0210076A8 - Preparação de vírus da influenza inativado, vacina de influenza, método para a preparação de um antígeno de hemaglutinina estável, e, uso de alfa-tocoferol ou succinato - Google Patents
Preparação de vírus da influenza inativado, vacina de influenza, método para a preparação de um antígeno de hemaglutinina estável, e, uso de alfa-tocoferol ou succinatoInfo
- Publication number
- BRPI0210076A8 BRPI0210076A8 BRPI0210076A BRPI0210076A BRPI0210076A8 BR PI0210076 A8 BRPI0210076 A8 BR PI0210076A8 BR PI0210076 A BRPI0210076 A BR PI0210076A BR PI0210076 A BRPI0210076 A BR PI0210076A BR PI0210076 A8 BRPI0210076 A8 BR PI0210076A8
- Authority
- BR
- Brazil
- Prior art keywords
- preparation
- influenza
- tocopherol
- alpha
- sccinate
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
- C12N7/04—Inactivation or attenuation; Producing viral sub-units
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/145—Orthomyxoviridae, e.g. influenza virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5252—Virus inactivated (killed)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16161—Methods of inactivation or attenuation
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16211—Influenzavirus B, i.e. influenza B virus
- C12N2760/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Microbiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Pulmonology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biochemistry (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB0113083A GB0113083D0 (en) | 2001-05-30 | 2001-05-30 | Novel compounds |
GB0113083.0 | 2001-05-30 | ||
GB0204116.8 | 2002-02-21 | ||
GB0204116A GB0204116D0 (en) | 2002-02-21 | 2002-02-21 | Novel vaccine composition |
PCT/EP2002/005883 WO2002097072A2 (en) | 2001-05-30 | 2002-05-29 | Influenza vaccine composition |
Publications (4)
Publication Number | Publication Date |
---|---|
BR0210076A BR0210076A (pt) | 2004-06-22 |
BRPI0210076A8 true BRPI0210076A8 (pt) | 2017-05-23 |
BRPI0210076B1 BRPI0210076B1 (pt) | 2020-01-07 |
BRPI0210076B8 BRPI0210076B8 (pt) | 2021-05-25 |
Family
ID=30445235
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI0210076 BRPI0210076B8 (pt) | 2001-05-30 | 2002-05-29 | preparação de vírus da influenza inativado, vacina de influenza, método para a preparação de um antígeno de hemaglutinina estável, e, uso de alfa-tocoferol ou succinato |
Country Status (30)
Country | Link |
---|---|
US (2) | US7316813B2 (pt) |
EP (3) | EP2495314A1 (pt) |
JP (1) | JP4074582B2 (pt) |
KR (1) | KR100871021B1 (pt) |
CN (2) | CN1279165C (pt) |
AR (1) | AR036039A1 (pt) |
AT (1) | ATE420159T1 (pt) |
AU (2) | AU2006200742C9 (pt) |
BR (1) | BRPI0210076B8 (pt) |
CA (1) | CA2448208C (pt) |
CO (1) | CO5540349A2 (pt) |
CY (1) | CY1108930T1 (pt) |
CZ (1) | CZ298697B6 (pt) |
DE (1) | DE60230760D1 (pt) |
DK (1) | DK1407008T3 (pt) |
ES (1) | ES2318020T3 (pt) |
FR (1) | FR13C0072I1 (pt) |
HK (1) | HK1067891A1 (pt) |
HU (1) | HU229368B1 (pt) |
IL (2) | IL158931A (pt) |
MX (1) | MXPA03010944A (pt) |
MY (1) | MY134424A (pt) |
NO (1) | NO335212B1 (pt) |
NZ (1) | NZ529755A (pt) |
PL (1) | PL206435B1 (pt) |
PT (1) | PT1407008E (pt) |
SI (1) | SI1407008T1 (pt) |
TW (1) | TWI228420B (pt) |
WO (1) | WO2002097072A2 (pt) |
ZA (1) | ZA200309250B (pt) |
Families Citing this family (111)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU764368B2 (en) * | 1999-09-24 | 2003-08-14 | Smithkline Beecham Biologicals (Sa) | Intranasal influenza virus vaccine |
GB9923176D0 (en) | 1999-09-30 | 1999-12-01 | Smithkline Beecham Biolog | Novel composition |
US20100221284A1 (en) * | 2001-05-30 | 2010-09-02 | Saech-Sisches Serumwerk Dresden | Novel vaccine composition |
MY134424A (en) * | 2001-05-30 | 2007-12-31 | Saechsisches Serumwerk | Stable influenza virus preparations with low or no amount of thiomersal |
US20060110406A1 (en) | 2003-02-25 | 2006-05-25 | Medimmune Vaccines, Inc. | Refrigerator-temperature stable influenza vaccine compositions |
KR101251902B1 (ko) | 2003-02-25 | 2013-04-08 | 메디뮨 엘엘씨 | 인플루엔자 백신 조성물의 제조 방법 |
CA2890962A1 (en) | 2004-09-09 | 2006-03-16 | Novartis Vaccines And Diagnostics Gmbh & Co. Kg | Decreasing potential iatrogenic risks associated with influenza vaccines |
EP2769735B1 (en) * | 2004-10-06 | 2017-04-19 | MedImmune, LLC | Refrigerator-temperature stable influenza vaccine compositions |
CA2586690A1 (en) * | 2004-11-03 | 2006-06-15 | Novartis Vaccines And Diagnostics, Inc. | Influenza vaccination |
US9161905B2 (en) * | 2005-01-12 | 2015-10-20 | Ocular Research Of Boston, Inc. | Dry eye treatment |
NZ561823A (en) | 2005-03-23 | 2010-04-30 | Glaxosmithkline Biolog Sa | Use of an influenza virus and an oil-in-water emulsion adjuvant to induce cd4 t-cell and/or improved b-memory cell response |
AP2745A (en) * | 2005-08-02 | 2013-09-30 | Novartis Vaccines & Diagnostic | Reducing interference between oil-containing adjuvants and surfactant-containing antigens |
NZ567817A (en) | 2005-11-01 | 2012-01-12 | Novartis Vaccines & Diagnostic | Cell-derived viral vaccines with low levels of residual cell DNA by beta-propiolactone treatment |
US11707520B2 (en) | 2005-11-03 | 2023-07-25 | Seqirus UK Limited | Adjuvanted vaccines with non-virion antigens prepared from influenza viruses grown in cell culture |
CN102727885A (zh) | 2005-11-04 | 2012-10-17 | 诺华疫苗和诊断有限公司 | 包含颗粒佐剂和免疫增强剂组合的流感疫苗 |
WO2007052061A2 (en) * | 2005-11-04 | 2007-05-10 | Novartis Vaccines And Diagnostics Srl | Emulsions with free aqueous-phase surfactant as adjuvants for split influenza vaccines |
DK2368572T3 (da) | 2005-11-04 | 2020-05-25 | Seqirus Uk Ltd | Adjuvansvacciner med ikke-virionantigener fremstillet fra influenza-virusser dyrket i cellekultur |
US20090304742A1 (en) * | 2005-11-04 | 2009-12-10 | Novartis Vaccines And Diagnostics Srl | Influenza vaccines with reduced amount of emulsion adjuvant |
JP2009514839A (ja) | 2005-11-04 | 2009-04-09 | ノバルティス ヴァクシンズ アンド ダイアグノスティクス エスアールエル | サイトカイン誘導剤を含むアジュバントインフルエンザワクチン |
TWI457133B (zh) | 2005-12-13 | 2014-10-21 | Glaxosmithkline Biolog Sa | 新穎組合物 |
WO2007085969A2 (en) | 2006-01-27 | 2007-08-02 | Novartis Vaccines And Diagnostics Gmbh & Co Kg | Influenza vaccines containing hemagglutinin and matrix proteins |
JP2009534303A (ja) * | 2006-03-24 | 2009-09-24 | ノバルティス ヴァクシンズ アンド ダイアグノスティクス ゲーエムベーハー アンド カンパニー カーゲー | 冷蔵しないインフルエンザワクチンの保存 |
PL2054431T3 (pl) | 2006-06-09 | 2012-07-31 | Novartis Ag | Konformery adhezyn bakteryjnych |
EP2043682B1 (en) | 2006-07-17 | 2014-04-02 | GlaxoSmithKline Biologicals S.A. | Influenza vaccine |
PT2043682E (pt) | 2006-07-17 | 2014-07-11 | Glaxosmithkline Biolog Sa | Vacina da influenza |
GB0614460D0 (en) | 2006-07-20 | 2006-08-30 | Novartis Ag | Vaccines |
CA3016948A1 (en) | 2006-09-11 | 2008-03-20 | Seqirus UK Limited | Making influenza virus vaccines without using eggs |
US8097419B2 (en) | 2006-09-12 | 2012-01-17 | Longhorn Vaccines & Diagnostics Llc | Compositions and method for rapid, real-time detection of influenza A virus (H1N1) swine 2009 |
US9481912B2 (en) | 2006-09-12 | 2016-11-01 | Longhorn Vaccines And Diagnostics, Llc | Compositions and methods for detecting and identifying nucleic acid sequences in biological samples |
US8080645B2 (en) | 2007-10-01 | 2011-12-20 | Longhorn Vaccines & Diagnostics Llc | Biological specimen collection/transport compositions and methods |
US8652782B2 (en) | 2006-09-12 | 2014-02-18 | Longhorn Vaccines & Diagnostics, Llc | Compositions and methods for detecting, identifying and quantitating mycobacterial-specific nucleic acids |
EP2086582B1 (en) | 2006-10-12 | 2012-11-14 | GlaxoSmithKline Biologicals s.a. | Vaccine comprising an oil in water emulsion adjuvant |
NZ577405A (en) | 2006-12-06 | 2012-08-31 | Novartis Ag | Vaccines including antigen from four strains of influenza virus |
TW200908994A (en) | 2007-04-20 | 2009-03-01 | Glaxosmithkline Biolog Sa | Vaccine |
CA2692200A1 (en) | 2007-06-27 | 2008-12-31 | Novartis Ag | Low-additive influenza vaccines |
US9683256B2 (en) | 2007-10-01 | 2017-06-20 | Longhorn Vaccines And Diagnostics, Llc | Biological specimen collection and transport system |
US11041215B2 (en) | 2007-08-24 | 2021-06-22 | Longhorn Vaccines And Diagnostics, Llc | PCR ready compositions and methods for detecting and identifying nucleic acid sequences |
US10004799B2 (en) | 2007-08-27 | 2018-06-26 | Longhorn Vaccines And Diagnostics, Llc | Composite antigenic sequences and vaccines |
EP2772267B1 (en) | 2007-08-27 | 2016-04-27 | Longhorn Vaccines and Diagnostics, LLC | Immunogenic compositions and methods |
BRPI0816130A2 (pt) * | 2007-08-28 | 2015-02-24 | Baxter Int | Métodos para a fabricação de uma preparação e para aumentar a resistência a uma infecção viral em um indivíduo. |
DK2535428T3 (en) | 2007-10-01 | 2015-11-23 | Longhorn Vaccines & Diagnostics Llc | Biological prøvesamlings- and transport system, and methods of using |
US11041216B2 (en) | 2007-10-01 | 2021-06-22 | Longhorn Vaccines And Diagnostics, Llc | Compositions and methods for detecting and quantifying nucleic acid sequences in blood samples |
GB0810305D0 (en) | 2008-06-05 | 2008-07-09 | Novartis Ag | Influenza vaccination |
GB0818453D0 (en) | 2008-10-08 | 2008-11-12 | Novartis Ag | Fermentation processes for cultivating streptococci and purification processes for obtaining cps therefrom |
CA2710480A1 (en) | 2007-12-24 | 2009-07-02 | Novartis Ag | Assays for adsorbed influenza vaccines |
US8506966B2 (en) * | 2008-02-22 | 2013-08-13 | Novartis Ag | Adjuvanted influenza vaccines for pediatric use |
EP2889042A3 (en) | 2008-03-18 | 2015-10-14 | Novartis AG | Improvements in preparation of influenza virus vaccine antigens |
RS54306B1 (en) | 2008-04-16 | 2016-02-29 | Glaxosmithkline Biologicals S.A. | THE VACCINE |
CA2741961A1 (en) | 2008-11-05 | 2010-05-14 | Glaxosmithkline Biologicals S.A. | Novel method |
US20120093860A1 (en) * | 2009-02-10 | 2012-04-19 | Novartis Ag | Influenza vaccines with increased amounts of h3 antigen |
PL2396032T3 (pl) | 2009-02-10 | 2017-05-31 | Seqirus UK Limited | Szczepionki przeciw grypie o obniżonych zawartościach skwalenu |
EP2942062A1 (en) | 2009-02-10 | 2015-11-11 | Novartis AG | Influenza vaccine regimens for pandemic-associated strains |
USH2284H1 (en) | 2009-04-27 | 2013-09-03 | Novartis Ag | Vaccines for protecting against influenza |
EP2401384B1 (en) | 2009-05-21 | 2012-10-03 | Novartis AG | Reverse genetics using non-endogenous pol i promoters |
US9907746B2 (en) | 2009-07-06 | 2018-03-06 | Variation Biotechnologies, Inc. | Methods for preparing vesicles and formulations produced therefrom |
CA2767392C (en) | 2009-07-06 | 2017-03-14 | Variation Biotechnologies, Inc. | Methods for preparing vesicles and formulations produced therefrom |
AU2010277310B2 (en) | 2009-07-31 | 2015-01-15 | Seqirus UK Limited | Reverse genetics systems |
SG178904A1 (en) | 2009-09-10 | 2012-04-27 | Novartis Ag | Combination vaccines against respiratory tract diseases |
PL2491117T3 (pl) | 2009-10-20 | 2014-05-30 | Novartis Ag | Udoskonalone sposoby odzyskiwania wirusa wykorzystujące odwrotną genetykę |
GB0918830D0 (en) * | 2009-10-27 | 2009-12-09 | Glaxosmithkline Biolog Niederl | Process |
GB0919117D0 (en) | 2009-10-30 | 2009-12-16 | Glaxosmithkline Biolog Sa | Process |
DE102009056871A1 (de) | 2009-12-03 | 2011-06-22 | Novartis AG, 4056 | Impfstoff-Adjuvantien und verbesserte Verfahren zur Herstellung derselben |
DE102009056884B4 (de) | 2009-12-03 | 2021-03-18 | Novartis Ag | Impfstoff-Adjuvantien und verbesserte Verfahren zur Herstellung derselben |
BR112012013426B8 (pt) | 2009-12-03 | 2021-05-25 | Novartis Ag | métodos para a fabricação de uma emulsão de óleo-em-água, para preparar uma composição de vacina e para preparar um kit de vacina |
DE102009056883B4 (de) | 2009-12-03 | 2012-08-16 | Novartis Ag | Impfstoff-Adjuvantien und verbesserte Verfahren zur Herstellung derselben |
EP2601933B1 (en) | 2009-12-03 | 2015-10-07 | Novartis AG | Hydrophilic filtration during manufacture of vaccine adjuvants |
FI2638895T3 (fi) | 2009-12-03 | 2024-06-20 | Seqirus Uk Ltd | Ainesosien kierrätys emulsioiden homogenisoinnin aikana |
KR20130048208A (ko) | 2010-03-11 | 2013-05-09 | 이뮨 디자인 코포레이션 | 인플루엔자 백신 |
JP6072677B2 (ja) | 2010-05-06 | 2017-02-01 | ノバルティス アーゲー | 微生物の不活化のための有機ペルオキシド化合物 |
WO2011141819A1 (en) | 2010-05-12 | 2011-11-17 | Novartis Ag | Improved methods for preparing squalene |
CN103025350A (zh) | 2010-05-21 | 2013-04-03 | 诺华有限公司 | 流感病毒的重配方法 |
CA2801149A1 (en) | 2010-06-01 | 2011-12-08 | Novartis Ag | Concentration of vaccine antigens without lyophilization |
PL2575873T3 (pl) | 2010-06-01 | 2016-06-30 | Novartis Ag | Zatężanie i liofilizacja antygenów szczepionkowych grypy |
WO2011154976A2 (en) | 2010-06-08 | 2011-12-15 | Panacea Biotec Limited | Improved influenza vaccine |
CA2840079C (en) | 2010-07-06 | 2018-07-03 | Variation Biotechnologies Inc. | Compositions and methods for treating influenza |
CA2808965C (en) | 2010-08-20 | 2020-01-07 | Novartis Ag | Soluble needle arrays for delivery of influenza vaccines |
CA2812135A1 (en) | 2010-09-07 | 2012-03-15 | Novartis Ag | Generic assays for detection of mammalian reovirus |
CA2815275C (en) | 2010-10-27 | 2023-09-19 | Glaxosmithkline Biologicals S.A. | Immunogenic compositions derived from shigella |
WO2012097346A1 (en) | 2011-01-13 | 2012-07-19 | Variation Biotechnologies, Inc. | Compositions and methods for treating viral infections |
AU2012205315B2 (en) | 2011-01-13 | 2017-05-04 | Variation Biotechnologies, Inc. | Methods for preparing vesicles and formulations produced therefrom |
JP5798356B2 (ja) * | 2011-04-06 | 2015-10-21 | 一般財団法人化学及血清療法研究所 | 新規インフルエンザワクチン安定化剤 |
GB201216121D0 (en) | 2012-09-10 | 2012-10-24 | Novartis Ag | Sample quantification by disc centrifugation |
CA2852857A1 (en) | 2011-10-20 | 2013-04-25 | Novartis Ag | Adjuvanted influenza b virus vaccines for pediatric priming |
US20140328876A1 (en) | 2011-11-18 | 2014-11-06 | Variation Biotechnologies Inc. | Synthetic derivatives of mpl and uses thereof |
EP2802353A4 (en) | 2012-01-12 | 2015-12-02 | Variation Biotechnologies Inc | COMPOSITIONS AND METHOD FOR THE TREATMENT OF VIRUS INFECTIONS |
CA3207612A1 (en) | 2012-01-26 | 2013-08-01 | Longhorn Vaccines And Diagnostics, Llc | Composite antigenic sequences and vaccines |
US20150079077A1 (en) | 2012-01-27 | 2015-03-19 | Variation Biotechnologies, Inc. | Methods and compositions for therapeutic agents |
ES2628301T3 (es) | 2012-03-02 | 2017-08-02 | Seqirus UK Limited | Recombinación de virus de gripe |
GB201205189D0 (en) | 2012-03-23 | 2012-05-09 | Glaxosmithkline Biolog Sa | Novel medical use |
US20130315955A1 (en) * | 2012-04-13 | 2013-11-28 | Protein Sciences Corporation | Stability and potency of hemagglutinin |
WO2013182498A1 (en) | 2012-06-04 | 2013-12-12 | Novartis Ag | Improved safety testing |
GB201218195D0 (en) | 2012-10-10 | 2012-11-21 | Istituto Zooprofilattico Sperimentale Delle Venezie | Composition |
MX2015006927A (es) | 2012-12-03 | 2016-02-05 | Novartis Ag | Redistribucion de virus de la influenza. |
WO2014108515A1 (en) | 2013-01-10 | 2014-07-17 | Novartis Ag | Influenza virus immunogenic compositions and uses thereof |
CN111334530A (zh) | 2013-03-13 | 2020-06-26 | 诺华股份有限公司 | 乙型流感病毒重配 |
JP2016521282A (ja) | 2013-05-10 | 2016-07-21 | ノバルティス アーゲー | インフルエンザワクチンにおけるナルコレプシーのリスクの回避 |
DE202013005130U1 (de) | 2013-06-05 | 2013-09-10 | Novartis Ag | Influenza Virus Reassortierung |
DE202013005100U1 (de) | 2013-06-05 | 2013-08-26 | Novartis Ag | Influenza Virus Reassortierung |
BR112015030582A2 (pt) | 2013-06-06 | 2017-08-29 | Novartis Ag | Segmento de hemaglutinina da gripe quimérico e de neuraminidase quimérico, proteína de hemaglutinina quimérica, vírus da gripe rearranjado, métodos para preparação de um vírus da gripe rearranjado e para preparação de uma vacina e sistema de expressão |
CN104436157A (zh) | 2013-09-23 | 2015-03-25 | 恩金生物有限公司 | 流感疫苗和治疗 |
JP6487850B2 (ja) * | 2013-11-29 | 2019-03-20 | テルモ株式会社 | アジュバント組成物およびこれを含むワクチン組成物、並びにこれらの製造方法 |
WO2016087479A1 (en) | 2014-12-02 | 2016-06-09 | Novartis Ag | Manufacture of surfactant-containing compositions |
WO2016183292A1 (en) | 2015-05-14 | 2016-11-17 | Longhorn Vaccines And Diagnostics, Llc | Rapid methods for the extraction of nucleic acids from biological samples |
JP2018524323A (ja) | 2015-06-26 | 2018-08-30 | セキラス ユーケー リミテッド | 抗原がマッチしたインフルエンザワクチン |
US10416171B2 (en) | 2015-07-07 | 2019-09-17 | Seqirus UK Limited | Influenza potency assays |
WO2017167768A1 (en) | 2016-03-28 | 2017-10-05 | Glaxosmithkline Biologicals S.A. | Novel vaccine composition |
GB201614799D0 (en) * | 2016-09-01 | 2016-10-19 | Glaxosmithkline Biologicals Sa | Compositions |
CA3127639A1 (en) | 2019-01-30 | 2020-08-06 | Glaxosmithkline Biologicals Sa | Oil/surfactant mixtures for self-emulsification |
MX2022006005A (es) | 2019-11-18 | 2022-10-27 | Seqirus Pty Ltd | Metodo para producir virus de la influenza reagrupados. |
RU2754398C1 (ru) * | 2020-06-25 | 2021-09-01 | Общество с ограниченной ответственностью «ФОРТ» | Способ получения четырехвалентной вакцины для профилактики гриппа |
EP4171514A1 (en) | 2020-06-30 | 2023-05-03 | Seqirus UK Limited | Cold filtration of oil-in-water emulsion adjuvants |
Family Cites Families (71)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5520A (en) | 1848-04-18 | Oegan-pipb | ||
US639A (en) | 1838-03-17 | of boston | ||
US4270537A (en) | 1979-11-19 | 1981-06-02 | Romaine Richard A | Automatic hypodermic syringe |
DD155875A1 (de) | 1980-12-31 | 1982-07-14 | Willy Nordheim | Verfahren zur herstellung eines ballaststoffarmen inaktivierten influenzaimpfstoffes |
US4436727A (en) | 1982-05-26 | 1984-03-13 | Ribi Immunochem Research, Inc. | Refined detoxified endotoxin product |
DD211444A3 (de) | 1982-08-19 | 1984-07-11 | Saechsisches Serumwerk | Verfahren zur herstellung von influenza-impfstoffen |
SE8205892D0 (sv) | 1982-10-18 | 1982-10-18 | Bror Morein | Immunogent membranproteinkomplex, sett for framstellning och anvendning derav som immunstimulerande medel och sasom vaccin |
US4596556A (en) | 1985-03-25 | 1986-06-24 | Bioject, Inc. | Hypodermic injection apparatus |
DD300833A7 (de) | 1985-10-28 | 1992-08-13 | Saechsische Landesgewerbefoerd | Verfahren zur herstellung von inaktivierten influenza-vollvirusimpfstoffen |
CA1283827C (en) | 1986-12-18 | 1991-05-07 | Giorgio Cirelli | Appliance for injection of liquid formulations |
GB8704027D0 (en) | 1987-02-20 | 1987-03-25 | Owen Mumford Ltd | Syringe needle combination |
US5057540A (en) | 1987-05-29 | 1991-10-15 | Cambridge Biotech Corporation | Saponin adjuvant |
CA1331443C (en) | 1987-05-29 | 1994-08-16 | Charlotte A. Kensil | Saponin adjuvant |
US4941880A (en) | 1987-06-19 | 1990-07-17 | Bioject, Inc. | Pre-filled ampule and non-invasive hypodermic injection device assembly |
US4940460A (en) | 1987-06-19 | 1990-07-10 | Bioject, Inc. | Patient-fillable and non-invasive hypodermic injection device assembly |
US4790824A (en) | 1987-06-19 | 1988-12-13 | Bioject, Inc. | Non-invasive hypodermic injection device |
US5339163A (en) | 1988-03-16 | 1994-08-16 | Canon Kabushiki Kaisha | Automatic exposure control device using plural image plane detection areas |
US4912094B1 (en) | 1988-06-29 | 1994-02-15 | Ribi Immunochem Research Inc. | Modified lipopolysaccharides and process of preparation |
FR2638359A1 (fr) | 1988-11-03 | 1990-05-04 | Tino Dalto | Guide de seringue avec reglage de la profondeur de penetration de l'aiguille dans la peau |
AU626049B2 (en) * | 1989-05-29 | 1992-07-23 | Lion Corporation | Method for preparing vaccine for dental caries and vaccinal compositions for dental caries used as nasal drop |
US5064413A (en) | 1989-11-09 | 1991-11-12 | Bioject, Inc. | Needleless hypodermic injection device |
US5312335A (en) | 1989-11-09 | 1994-05-17 | Bioject Inc. | Needleless hypodermic injection device |
US5190521A (en) | 1990-08-22 | 1993-03-02 | Tecnol Medical Products, Inc. | Apparatus and method for raising a skin wheal and anesthetizing skin |
US5527288A (en) | 1990-12-13 | 1996-06-18 | Elan Medical Technologies Limited | Intradermal drug delivery device and method for intradermal delivery of drugs |
GB9118204D0 (en) | 1991-08-23 | 1991-10-09 | Weston Terence E | Needle-less injector |
SE9102652D0 (sv) | 1991-09-13 | 1991-09-13 | Kabi Pharmacia Ab | Injection needle arrangement |
CA2085827C (en) | 1991-12-23 | 2003-10-14 | Lucas A. T. Hilgers | Adjuvant composition containing synthetic hydrophobic lipopolysaccharide |
IL101007A (en) * | 1992-02-18 | 1997-08-14 | Pharmos Ltd | Dry stable compositions prepared by lyophilization |
US5328483A (en) | 1992-02-27 | 1994-07-12 | Jacoby Richard M | Intradermal injection device with medication and needle guard |
JP3755890B2 (ja) | 1992-06-25 | 2006-03-15 | スミスクライン・ビーチャム・バイオロジカルス(ソシエテ・アノニム) | アジュバント含有ワクチン組成物 |
US5383851A (en) | 1992-07-24 | 1995-01-24 | Bioject Inc. | Needleless hypodermic injection device |
US5569189A (en) | 1992-09-28 | 1996-10-29 | Equidyne Systems, Inc. | hypodermic jet injector |
US5334144A (en) | 1992-10-30 | 1994-08-02 | Becton, Dickinson And Company | Single use disposable needleless injector |
EP0812593B8 (en) | 1993-03-23 | 2010-11-10 | SmithKline Beecham Biologicals S.A. | Vaccine compositions containing 3-0 deacylated monophosphoryl lipid a |
AU5543294A (en) * | 1993-10-29 | 1995-05-22 | Pharmos Corp. | Submicron emulsions as vaccine adjuvants |
GB9326253D0 (en) * | 1993-12-23 | 1994-02-23 | Smithkline Beecham Biolog | Vaccines |
WO1995024176A1 (en) | 1994-03-07 | 1995-09-14 | Bioject, Inc. | Ampule filling device |
US5466220A (en) | 1994-03-08 | 1995-11-14 | Bioject, Inc. | Drug vial mixing and transfer device |
US5616487A (en) * | 1994-09-15 | 1997-04-01 | Aastrom Biosciences, Inc. | Stabilized retrovirus compositions |
AUPM873294A0 (en) | 1994-10-12 | 1994-11-03 | Csl Limited | Saponin preparations and use thereof in iscoms |
US5599302A (en) | 1995-01-09 | 1997-02-04 | Medi-Ject Corporation | Medical injection system and method, gas spring thereof and launching device using gas spring |
UA56132C2 (uk) | 1995-04-25 | 2003-05-15 | Смітклайн Бічем Байолоджікалс С.А. | Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини |
US5730723A (en) | 1995-10-10 | 1998-03-24 | Visionary Medical Products Corporation, Inc. | Gas pressured needle-less injection device and method |
ATE214603T1 (de) | 1995-06-30 | 2002-04-15 | American Cyanamid Co | Stabile makrolide und makrolide imptstoff- zusammensetzungen |
US20020165168A1 (en) * | 1995-12-16 | 2002-11-07 | Joachim Bunger | Use of sugar derivatives as antimicrobial, antimycotic and/or antiviral active substances |
US5893397A (en) | 1996-01-12 | 1999-04-13 | Bioject Inc. | Medication vial/syringe liquid-transfer apparatus |
GB9607549D0 (en) | 1996-04-11 | 1996-06-12 | Weston Medical Ltd | Spring-powered dispensing device |
US5919480A (en) * | 1996-06-24 | 1999-07-06 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Liposomal influenza vaccine composition and method |
US6403098B1 (en) | 1996-09-26 | 2002-06-11 | Merck & Co., Inc. | Rotavirus vaccine formulations |
DE19649895A1 (de) * | 1996-12-02 | 1998-06-04 | Henkel Kgaa | Schäumende Körperreinigungsmittel |
ATE444760T1 (de) * | 1997-01-13 | 2009-10-15 | Univ Emory | Glutathion zur behandlung von influenzainfektionen |
GB9705740D0 (en) * | 1997-03-20 | 1997-05-07 | Medeva Europ Ltd | A method of preservation |
EP0971739B1 (en) | 1997-04-01 | 2004-10-06 | Corixa Corporation | Aqueous immunologic adjuvant compositions of monophosphoryl lipid a |
US5993412A (en) | 1997-05-19 | 1999-11-30 | Bioject, Inc. | Injection apparatus |
GB9711990D0 (en) | 1997-06-11 | 1997-08-06 | Smithkline Beecham Biolog | Vaccine |
JP4426091B2 (ja) * | 1997-09-05 | 2010-03-03 | グラクソスミスクライン バイオロジカルズ ソシエテ アノニム | サポニンを含有する水中油型エマルション |
IT1298087B1 (it) | 1998-01-08 | 1999-12-20 | Fiderm S R L | Dispositivo per il controllo della profondita' di penetrazione di un ago, in particolare applicabile ad una siringa per iniezioni |
KR20010042573A (ko) * | 1998-04-09 | 2001-05-25 | 장 스테판느 | 애쥬번트 조성물 |
FR2780278B1 (fr) * | 1998-06-24 | 2001-01-19 | Oreal | Composition conditionnante et detergente et utilisation |
DE19841796A1 (de) * | 1998-09-12 | 2000-03-16 | Beiersdorf Ag | Kombinationen von Antiadhäsiva (Kohlenhydrate) und Mikrobiziden |
DE60014076T2 (de) * | 1999-04-19 | 2005-10-13 | Glaxosmithkline Biologicals S.A. | Adjuvans-zusammensetzung, enthaltend saponin und ein immunstimulatorisches oligonukleotid |
AUPQ233799A0 (en) * | 1999-08-19 | 1999-09-09 | Minister For Agriculture, Minister For Land And Water Conservation For And On Behalf Of The State Of New South Wales | Recombinant sub-unit vaccine |
CN1391483A (zh) * | 1999-09-24 | 2003-01-15 | 史密丝克莱恩比彻姆生物有限公司 | 作为佐剂的聚氧乙烯脱水山梨醇酯和辛苯昔醇组合及其在疫苗中的应用 |
WO2001021152A1 (en) * | 1999-09-24 | 2001-03-29 | Smithkline Beecham Biologicals S.A. | Adjuvant comprising a polyxyethylene alkyl ether or ester and at least one nonionic surfactant |
AU764368B2 (en) * | 1999-09-24 | 2003-08-14 | Smithkline Beecham Biologicals (Sa) | Intranasal influenza virus vaccine |
US6494865B1 (en) | 1999-10-14 | 2002-12-17 | Becton Dickinson And Company | Intradermal delivery device including a needle assembly |
TR200201048T2 (tr) * | 1999-10-19 | 2002-08-21 | The Procter & Gamble Company | Soğuk algınlığı ve gribi andıran semptomların önlenmesi ve tedavisi için bileşimler |
AR030829A1 (es) * | 2000-10-02 | 2003-09-03 | Smithkline Beecham Biolog | Una formulacion de vacuna, procedimiento para la produccion de la misma, uso de dicha preparacion y un estuche para su administracion via intranasal |
US20040096463A1 (en) * | 2001-02-23 | 2004-05-20 | Nathalie Garcon | Novel vaccine |
MY134424A (en) * | 2001-05-30 | 2007-12-31 | Saechsisches Serumwerk | Stable influenza virus preparations with low or no amount of thiomersal |
US9856414B2 (en) | 2013-06-10 | 2018-01-02 | Dober Chemical Corp. | Compositions, systems and methods of making coated additive components |
-
2002
- 2002-05-28 MY MYPI20021956A patent/MY134424A/en unknown
- 2002-05-28 TW TW091111304A patent/TWI228420B/zh not_active IP Right Cessation
- 2002-05-29 EP EP12170561A patent/EP2495314A1/en not_active Withdrawn
- 2002-05-29 EP EP09100013A patent/EP2039761A1/en not_active Ceased
- 2002-05-29 EP EP02743125A patent/EP1407008B1/en not_active Expired - Lifetime
- 2002-05-29 CA CA2448208A patent/CA2448208C/en not_active Expired - Lifetime
- 2002-05-29 MX MXPA03010944A patent/MXPA03010944A/es active IP Right Grant
- 2002-05-29 KR KR1020037015649A patent/KR100871021B1/ko active IP Right Grant
- 2002-05-29 AU AU2006200742A patent/AU2006200742C9/en active Active
- 2002-05-29 HU HU0400445A patent/HU229368B1/hu unknown
- 2002-05-29 AU AU2002344182A patent/AU2002344182C1/en not_active Expired
- 2002-05-29 CN CNB028146557A patent/CN1279165C/zh not_active Expired - Lifetime
- 2002-05-29 DE DE60230760T patent/DE60230760D1/de not_active Expired - Lifetime
- 2002-05-29 PT PT02743125T patent/PT1407008E/pt unknown
- 2002-05-29 US US10/480,952 patent/US7316813B2/en not_active Expired - Lifetime
- 2002-05-29 SI SI200230806T patent/SI1407008T1/sl unknown
- 2002-05-29 CN CN2006101156101A patent/CN101069744B/zh not_active Expired - Lifetime
- 2002-05-29 JP JP2003500240A patent/JP4074582B2/ja not_active Expired - Lifetime
- 2002-05-29 ES ES02743125T patent/ES2318020T3/es not_active Expired - Lifetime
- 2002-05-29 PL PL366990A patent/PL206435B1/pl unknown
- 2002-05-29 CZ CZ20033253A patent/CZ298697B6/cs unknown
- 2002-05-29 BR BRPI0210076 patent/BRPI0210076B8/pt not_active IP Right Cessation
- 2002-05-29 DK DK02743125T patent/DK1407008T3/da active
- 2002-05-29 NZ NZ529755A patent/NZ529755A/en not_active IP Right Cessation
- 2002-05-29 WO PCT/EP2002/005883 patent/WO2002097072A2/en active Application Filing
- 2002-05-29 AT AT02743125T patent/ATE420159T1/de active
- 2002-05-30 AR ARP020102018A patent/AR036039A1/es not_active Application Discontinuation
-
2003
- 2003-11-18 IL IL158931A patent/IL158931A/en active IP Right Grant
- 2003-11-24 NO NO20035208A patent/NO335212B1/no not_active IP Right Cessation
- 2003-11-27 ZA ZA2003/09250A patent/ZA200309250B/en unknown
- 2003-11-27 CO CO03104769A patent/CO5540349A2/es active IP Right Grant
-
2004
- 2004-10-13 HK HK04107894.8A patent/HK1067891A1/xx not_active IP Right Cessation
-
2007
- 2007-10-18 US US11/874,647 patent/US20080181914A1/en not_active Abandoned
-
2008
- 2008-01-17 IL IL188834A patent/IL188834A/en active IP Right Grant
-
2009
- 2009-03-26 CY CY20091100357T patent/CY1108930T1/el unknown
-
2013
- 2013-12-18 FR FR13C0072C patent/FR13C0072I1/fr active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BRPI0210076A8 (pt) | Preparação de vírus da influenza inativado, vacina de influenza, método para a preparação de um antígeno de hemaglutinina estável, e, uso de alfa-tocoferol ou succinato | |
BR112022024248A2 (pt) | Vacinas de combinação à base de ácido nucleico | |
ES2357752T3 (es) | Reducción de riesgos latrogénicos potenciales asocidos con vacunas. | |
JP2004527264A5 (pt) | ||
BR9911163A (pt) | Formulação de vacina, formulação farmacêutica, vìrus atenuado de influenza, processos para vacinar um indivìduo, para prevenir uma doença infecciosa em um indivìduo, e, para tratar ou prevenir tumores em um indivìduo | |
BRPI0707300A8 (pt) | Vacina contra vírion influenza dividido ou antígeno de superfície purificado e método para a preparação de uma composição imunogênica | |
BR0014281A (pt) | Vacina contra vìrus de gripe intranasal | |
BR0114393A (pt) | Uso de uma preparação de vìrus envelopado dividido, método para produzir uma formulação de vacina intranasal, uso de uma preparação de vacina de vìrus envolopado dividido, kit para liberação de uma formulação de vacina intranasal, dispositivo de liberação intranasal, e, método para proteger ou tratar um mamìfero susceptìvel a, ou sofrendo de doença causada por vìrus envelopado | |
BRPI0208183B8 (pt) | peptídeo antígeno de câncer modificado por wt1 e vacinas para câncer | |
BR0208301A (pt) | Vacinas de ácido nucléico para prevenção de infecção por flavivìrus | |
BR0307524A (pt) | Composição farmacêutica para inibidores de protease viral de hepatite c | |
BR0312474A (pt) | Partìcula viral adjuvante | |
RU2008119501A (ru) | Функциональные вирусоподоюные частицы гриппа (vlps) | |
ME00491B (me) | Vakcina protiv bolesti zapadnog nila | |
NO985821L (no) | Substituerte syklopentanforbindelser som er nyttige som neuraminidaseinhibitorer | |
BR112022017923A2 (pt) | Tratamento de infecção por coronavírus | |
NZ592713A (en) | Adjuvanted influenza vaccines including a cytokine-inducing agents other than an agonist of Toll-Like Receptor 9 | |
BR0111366A (pt) | Vacina de poxvìrus recombinante do vìrus da sìndrome respiratória e reprodutiva de porcino (prrsv) | |
BR0207752A (pt) | Composto, sais de sódio, cálcio, potássio, magnésio, colina, etanolamina e trietilamina dos compostos, formas dos mesmos, métodos de tratamento ou de prevenção de uma infeção viral em um ser humano e de tratamento dos vìrus mutantes hiv uso de um composto, composição farmacêutica, e, processo para a preparação dos compostos | |
AR051636A1 (es) | Vacunas multivalentes para la gripe aviar | |
BR0317544A (pt) | Uso de uma composição que compreende vlps de hpv 16 e hpv 18, e, métodos para induzir uma resposta imune contra um ou mais do grupo de tipos de hpv oncogênicos, para prevenir infecção e/ou doença causada por um ou mais do grupo de tipos de hpv oncogênicos, para prevenir a infecção de uma população de pacientes por um ou mais tipos de hpv, uso de uma mistura de vlps de hpv 16 e hpv18, e, composição de vacina | |
BR0112497A (pt) | Antìgenos de streptococcus pyogenes | |
CO5280138A1 (es) | Virus atenuados e inocuos de la diarrea virica bovina para en vacas gestantes | |
BR9916893A (pt) | Tratamento | |
BRPI0417680A (pt) | plasma sangüìneo inativado de vìrus universalmente aplicável produzido a partir das porções de plasma não-caucasiano |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B15K | Others concerning applications: alteration of classification |
Free format text: A CLASSIFICACAO ANTERIOR ERA: C12N 7/04 Ipc: C12N 7/04 (2006.01), A61K 39/145 (2006.01), A61P 3 |
|
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
B25D | Requested change of name of applicant approved |
Owner name: GLAXOSMITHKLINE BIOLOGICALS BRANCH OF SMITHKLINE B |
|
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] |
Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI |
|
B06T | Formal requirements before examination [chapter 6.20 patent gazette] | ||
B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 07/01/2020, OBSERVADAS AS CONDICOES LEGAIS. |
|
B16C | Correction of notification of the grant [chapter 16.3 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 29/05/2002 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF |
|
B21A | Patent or certificate of addition expired [chapter 21.1 patent gazette] |
Free format text: PATENTE EXTINTA EM 29/05/2022 |